What AEON Biopharma does

AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX® for therapeutic indications in the U.S. market. The company licenses the 900 kDa botulinum toxin type A complex from Daewoong Pharmaceutical — the same molecule approved for aesthetic use in the U.S. (as Jeuveau/Nuceiva), EU, Canada, and 69 countries worldwide. AEON is exclusively focused on therapeutic indications such as cervical dystonia and chronic migraine, deliberately excluding aesthetic use, and is pursuing full-label therapeutic approval through the FDA biosimilar pathway using analytical similarity evidence rather than indication-by-indication clinical trials.

The company targets the U.S. therapeutic neurotoxin market, which exceeds $3.0 billion annually, with a planned payer-aligned pricing and access strategy. AEON is pre-revenue; net loss was $36.63 million for the most recent period reported, and all funding has been sourced from capital markets and Daewoong. Material financings include a March 2024 senior secured convertible note from Daewoong ($15M), a January 2025 public offering (~$20M), and a November 2025 combined transaction of up to $22M via PIPE and Daewoong note exchange that eliminated over 90% of outstanding debt. A January 2026 FDA BPD Type 2a meeting returned constructive feedback on AEON's analytical similarity strategy, and a BPD Type 2b meeting is planned to advance the program toward full-label therapeutic approval.

AEON has undergone significant leadership restructuring, including the April 2025 appointment of Robert Bancroft (formerly of Allergan, Revance, and Smith & Nephew) as President & CEO and the March 9, 2026 appointment of John Bencich as CFO. The company has 1-10 employees and is headquartered in Irvine, California. It received a NYSE American continued-listing non-compliance notice in 2025 and faces a going concern qualification from its auditor, with cash expected to fund operations only into Q3 2026. AEON also acquired Priveterra on December 12, 2022 for an undisclosed amount.

Name

AEON Biopharma

Legal name

AEON Biopharma, Inc.

Website

https://aeonbiopharma.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX® for therapeutic indications including cervical dystonia and chronic migraine in the U.S. therapeutic neurotoxin market.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Therapeutic Botulinum Toxin Biosimilars

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Botulinum toxin biosimilar
• Therapeutic neurotoxin
• Biosimilar pharmaceuticals
• Neuromuscular disorder treatments
• FDA biosimilar pathway

Headquarters

HQ city

Newport Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. ABP-450 Biosimilar Commercialization: AEON Biopharma is a clinical-stage biopharmaceutical company with no current product revenue. The company is developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX® for therapeutic indications. Upon FDA approval, the company intends to commercialize ABP-450 in the U.S. therapeutic neurotoxin market, which exceeds $3.0 billion annually. Revenue would be generated through pharmaceutical product sales, with a pricing and access strategy focused on expanding treatment access and delivering value to the healthcare system.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) as a branded biosimilar to BOTOX for therapeutic indications such as cervical dystonia and chronic migraine. The company leverages the FDA biosimilar pathway, an FDA-inspected manufacturing platform, and a 900 kDa botulinum toxin complex approved in 69 countries to target the U.S. therapeutic neurotoxin market (exceeding $3.0 billion annually). AEON focuses exclusively on therapeutic indications, not aesthetic use.

Product overview

AEON Biopharma is a clinical-stage biopharmaceutical company with a single core product focus: ABP-450 (prabotulinumtoxinA), a branded biosimilar to BOTOX. The company is exclusively focused on therapeutic botulinum toxin indications (not aesthetic use), leveraging FDA's biosimilar pathway to advance ABP-450 toward full-label therapeutic approval. AEON licenses the botulinum toxin complex from Daewoong Pharmaceutical and aims to address the $3+ billion U.S. therapeutic neurotoxin market by expanding access to botulinum toxin treatments for neuromuscular conditions such as cervical dystonia and chronic migraine.

Differentiator

Problem solved

Functional benefit

Products and services

• ABP-450 (prabotulinumtoxinA) A 900 kDa botulinum toxin type A complex in clinical development as a branded biosimilar to BOTOX for therapeutic indications including cervical dystonia and chronic migraine in the U.S. market. It is the same botulinum toxin complex approved for aesthetic use in the U.S. (as Jeuveau), EU, Canada, and 69 countries worldwide. Aimed at healthcare providers, payers, and patients with neuromuscular conditions.

Quantifiable outcome

• ABP-450 demonstrated functional and structural equivalence to BOTOX® through genomic and assay analyses, reinforcing its potential for U.S. market entry.
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Daewoong Pharmaceutical Co., Ltd.core / flagshipStrategic or Co-development PartnerAEON licenses ABP-450 (prabotulinumtoxinA), a 900 kDa botulinum toxin type A complex, from Daewoong Pharmaceutical. ABP-450 is the same botulinum toxin complex approved for aesthetic use in the US (as Jeuveau/Nuceiva), EU, Canada, and 69 countries worldwide. Daewoong has provided clinical development support, financing, and is AEON's core strategic partner for the biosimilar program targeting the U.S. therapeutic neurotoxin market.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Allergan Aesthetics (AbbVie): Original developer and global market leader for BOTOX (onabotulinumtoxinA), the reference product AEON is targeting with its biosimilar. Directly comparable therapeutic neurotoxin franchise with overlapping cervical dystonia, chronic migraine, and spasticity indications.
• Ipsen: Global manufacturer of Dysport (abobotulinumtoxinA) for cervical dystonia, spasticity, and other therapeutic indications. Established therapeutic neurotoxin incumbent with overlapping label and similar regulatory pathway complexity.

Direct peers

• Evolus: Markets Jeuveau (prabotulinumtoxinA-xvfs) — the same 900 kDa botulinum toxin type A complex as ABP-450 — approved in the U.S. and 69 countries. Currently focused on aesthetics but the closest direct molecular peer, with potential therapeutic expansion that would directly compete with AEON.

Emerging players

• Hugel: South Korean manufacturer of botulinum toxin products including Letybo (letibotulinumtoxinA), approved in multiple global markets. Emerging global therapeutic neurotoxin player with FDA pathway development underway.
• Revance Therapeutics: Markets Daxxify (daxibotulinumtoxinA-lanm), a long-acting botulinum toxin approved in cervical dystonia and aesthetics. Led by AEON's CEO Rob Bancroft prior to his move; directly competes with ABP-450 in the therapeutic neurotoxin market AEON targets.

Others

• Daewoong Pharmaceutical: AEON's core strategic partner, licensor of ABP-450, manufacturer of the botulinum toxin complex, and convertible note holder with board representation. Strongly comparable as the originator of the underlying molecule AEON is commercializing in the U.S.

Regional players

• Medytox: South Korean developer of botulinum toxin products (Meditoxin/Innotox), primarily serving Asian and emerging markets. Comparable as an established regional botulinum toxin developer with U.S. ambitions.
• Lanzhou Institute of Biological Products: Chinese state-affiliated manufacturer of botulinum toxin type A products (BTXA/Hengli) primarily serving China and select emerging markets. Comparable as a regional botulinum toxin developer with global expansion ambitions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aeon-biopharma-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AEON Biopharma